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Background: In resource limited settings non-availability of CD4 count facility at the site could adversely affect the
ART roll out programme. Point of care CD4 enumerating equipments can make the CD4 count available at the site
of care and improve the patients’ management considerably. This study is aimed at determining the utility of a
Point of Care PIMA CD4 analyzer (Alere, Germany) in the field settings in India.
Method: The blood samples were collected from 1790 participants at 21 ART centers from different parts of the
country and tested using PIMA and the reference methods (FACSCalibur, FACSCount and CyFlow SL3). The paired
finger prick and venous blood samples from 175 participants were tested by the PIMA CD4 Analyzer and
then by FACSCalibur.
Result: The CD4 counts obtained by PIMA CD4 analyzer showed excellent correlation with the counts obtained by
the reference methods; for venous blood the Pearson’s r was 0.921, p < 0.001 and the relative bias was 0.2% (range:
-42 to 42%) and for finger prick samples, the Pearson’s r was 0.856 and the relative bias was −9.1% (range: -46% to
27%). For CD4 ranges; <250, 251–350, 351–500 and >500 cells/mm3, the differences in the median CD4 counts
obtained by the reference method and the PIMA analyzer were not significant (P > 0.05) and the relative bias were
low (−7 to 5.1%). The Intermachine comparison showed variation within the acceptable limit of%CV of 10%.
Conclusion: In the field settings, the POC PIMA CD4 analyzer gave CD4 counts comparable to the reference
methods for all CD4 ranges. The POC equipment could identify the patients eligible for ART in 91% cases. Adequate
training is necessary for finger prick sample collection for optimum results. Decentralization of CD4 testing by
making the CD4 counts available at primary health centers, especially in remote areas with minimum or no
infrastructure would reduce the missed visits and improve adherence of the patients.
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CD4 count estimation is a mainstay of monitoring the
HIV disease progression and initiation and monitoring
of anti-retroviral treatment (ART) [1-4]. The World
Health Organization (WHO) has recommended using
CD4 counts for initiation and monitoring of ART in
HIV infected individuals in recourse limited settings [1].
The scaling up of the public ART programmes increased* Correspondence: mthakar@nariindia.org
1Department of Immunology, National AIDS Research Institute, G-73, MIDC,
Bhosari, Pune 411 026, India
Full list of author information is available at the end of the article
© 2012 Thakar et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the orthe demand for CD4 counts globally [5]. In a resource
limited setting CD4 count facility is not available in per-
ipheral areas and often the patients need to travel long
distances or the samples need to be transported to the
centres where the facility for CD4 count estimation is
available. This could be a barrier for expansion and
decentralization of the ART programme and adherence
to treatment.
A point of care CD4 assay may be able to fill this gap
and help in expanding the ART services and increase ad-
herence. The Point-Of-Care (POC) CD4 equipments will
be able to give the results in a very short time on theLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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another visit for collecting results. PIMA CD4 analyzer
(Alere) is one of the POC equipment. The closed dispos-
able cartridge used in the analyzer contains the reagents
required for the CD4+ T cell count estimation. It can
also work on finger prick sample and give results within
20 minutes of the sample collection. The validation
studies showed that the PIMA analyzer could give CD4
counts comparable to those obtained with the standard
flow cytometers such as FACSCount and FACSCalibur
[6-8]. For efficient working of the POC machines it is
important to know the accuracy of the PIMA analyzer at
different CD4 levels.
In the present study we assessed the feasibility of use
of PIMA POC CD4 analyzer in the field setting in Indian
ART programme. The PIMA CD4 analyzers were placed
at 21 different ART centers in different parts of the
country with maximum load of 25 patients per day. The
Intermachine comparisons and repeatability of the CD4
counts were assessed using venous blood samples. The
finger prick samples collected at the field settings were
also tested for the accuracy of CD4 counts in compari-
son with the paired venous samples.Methods
Study centres
The study was conducted at 21 ART centres having
minimum (5-10/day) to moderate (25-30/day) patient
load. Of these 21 centres, 2 had FACSCalibur, 13 had
FACSCount (both from Becton Dickinson, USA) and 6
had CyFlowW SL3 counter from Partec, Germany. All
these equipments are under the external proficiency as-
sessment conducted with Quality Assessment and
Standardization for Immunological measures relevant to
HIV/AIDS, Public Health Agency, Canada (QASI) for
the last three years and performing satisfactorily. Also
the inter machine comparison between these equipments
using fresh blood samples has been published earlier
[9,10]. These equipments were considered as reference
method in the study. The technologists from these cen-
ters were trained for two days for finger prick sample col-
lection and the CD4 count estimation using PIMA
analyzer including the use of calibrators. The equipments
were handed over to the technologists during training.Study participants
During June to August 2011, each centre consecutively
enrolled 5 to 10 HIV positive patients for CD4 count es-
timation every day after obtaining written informed con-
sent for CD4 count estimation. Approximately 100
patients were enrolled by each centre. The inclusion cri-
teria included age between 18 to 60 years and willing-
ness to give blood sample for CD4 count estimation.The paired finger prick and the venous blood samples
were collected at NARI, Pune from 175 HIV infected
individuals who gave written informed consent for col-
lection of finger prick samples.
Blood collection and processing
Three ml of venous blood sample was collected in K3
EDTA vacutainers. The capillary blood sample was col-
lected from the finger tip using lancet finger stick. A
puncture depth of 1.8 mm with a blade-type lancet (Sar-
stedt) was used to achieve sufficient capillary blood flow.
The venous or the finger prick samples were first tested
in the ART centre using PIMA CD4 analyzer and the
results were stored in the centre. The samples were then
sent to the attached laboratory for processing by the re-
spective reference methodologies. The technicians esti-
mating CD4 count by reference method were blinded
for PIMA results. The CD4 counts obtained by the refer-
ence method were provided to the patients.
CD4 count estimation
Test method- pima™ CD4
The samples were run in the PIMA CD4 analyzer only
after the normal and Low value control cartridges gave
acceptable value. After collection of venous sample,
25 μl of blood was immediately added to the PIMA CD4
cartridge. In case of finger prick sample, the sample was
directly collected on the cartridge. The cartridge was
capped and inserted immediately into the PIMA
analyzer. The PIMA analyzer works on volumetric
principle. Hence every time 5 μl of blood was drawn into
the detection channel of the PIMA cartridge from the
blood added in the receptacle.
During the incubation, freeze-dried fluorescently la-
beled antibodies (anti-CD3 and anti-CD4) get mixed
with the blood and the images of the CD3+ and CD4+
cells are captured by the camera and the results are then
expressed as cells/μl within 20 minutes. In the study, the
print out of the CD4 count obtained from the PIMA
analyzer was checked by the supervisor and stored in
the clinic itself.
Reference method-flow cytometry
In the laboratory, the blood samples were tested by re-
spective reference methodology on the day of collection.
The daily calibration and internal quality controls were
included in every run. The samples were acquired and ana-
lyzed only when the quality control indicators were passed.
FACSCalibur (Becton Dickinson, USA)
Twenty μL of liquid antibody reagent (MultiTEST CD3
FITC, CD4 PE, CD45 PerCP, Becton Dickinson, USA)
and 50 μL of whole blood was added to the TruCOUNT
tube (Becton Dickinson, USA) containing the reference
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450 μl of 1:10 diluted lysing solution for 15 minutes in
the dark at ambient temperature. The stained sample
was acquired on FACSCalibur (Becton Dickinson, USA)
and analyzed automatically using the MultiSET software
(BD Biosciences) by gating CD45+ T cells in first place
and these cells were further gated in CD3+CD4+ versus
CD3+CD4- T cells.
FACSCount (Becton Dickinson, USA)
Fifty μL of whole blood was added to FACSCount tube
containing CD3 PE /CD4 PE.Cychrome (PE.Cy5) mono-
clonal antibodies and a known number of reference
beads in a liquid format (Becton Dickinson, USA). After
incubation, 50 μL of fixative (5% formaldehyde in PBS)
was added. The stained sample was acquired and ana-
lyzed on the FACSCount using the automated analyzing
software by gating on CD3+CD4+ T cells.
CyFlowW SL3 (partec, Germany)
Twenty μL of whole blood and 20 μL of CD4-PE (Partec,
Germany) monoclonal antibody were added to the sam-
ple tube (Partec, Germany). After incubation, 800 μl of
no lyse buffer (Partec, Germany) was added into the
sample tube. The stained sample was then acquired on
the CyFlow SL_3. The acquired data was analyzed using
the inbuilt CyView software by gating on the histogram
of CD4+ T cells. The histogram and absolute counts are
displayed and printed automatically.. The results were
printed and stored after review.
Assessment of inter machine variation for PIMA
CD4 analyzer
Before distribution of the machines to respective centers,
the inter-machine variation was assessed by running the
commercially available stabilized blood samples with
Normal and low level CD4 count (Immuno Trol con-
trols, Beckman Coulter, USA) and 2 freshly collected
blood samples with low and high CD4 counts.
Additionally the onsite inter machine variation was
assessed using the low (CD4 count range: 129 to 201
cells/mm3) and normal (CD4 count range: 857 to 1075
cells/mm3) level PIMA Bead standards which were used
by these centers daily.
Statistical analysis
For assessing the precision as well as inter-machine vari-
ability amongst all 21 machines, the percent CV value
less than 10% was considered to be an acceptable value.
The Pearson’s correlation coefficient was used to esti-
mate the strength of the correlation between the CD4
counts obtained by the PIMA CD4 analyzer and the re-
spective reference methods. The data was analyzed using
Bland-Altman analysis to find out whether the methodsagree sufficiently well [11]. Since the data was collected
on a wide range of CD4 counts the relative bias was cal-
culated which is expected to normalize wide range of ab-
solute count data and thus would allow direct
comparison between PIMA and various reference meth-
ods. The relative bias was calculated by converting the
ratio of the difference between the CD4 counts obtained
from two machines and the average of both readings
into percentages.
Similar analyses were performed for comparison of the
finger prick sample with the venous sample. To deter-
mine the accuracy of the PIMA analyzer at different CD4
levels, the median values obtained for different CD4
ranges (<250, 251–350, 351–500 and >500 cells/mm3) by
both, the reference method and the PIMA analyzer were
compared. The relative bias was also calculated for these
CD4 ranges. To determine the clinical significance of the
variations in the CD4 estimations in the decision on
treatment initiation, the sensitivity and specificity of
PIMA CD4 analyzer to identify patients requiring ART
(CD4 count < 350 cells/μL) was determined.
Results
Before distribution, the inter machine variation for all 21
machines was assessed using fresh as well as stabilized
blood samples with high and low CD4 counts. Using the
stabilized blood samples, the% CV was found to be 4%
and 3% for low (130 cells/mm3) and high (649 cells/
mm3) Immuno Trol controls respectively. Whereas for
the freshly collected samples, the%CV was 10% for low
count (180 cells/ mm3) and 8% for the normal count
(749 cells/mm3). When the machines were installed on
site, the onsite variation was assessed by the values of
low and normal level PIMA Bead standards which were
used by all centers daily before processing the samples.
The mean% CV of all the centers for low control was
2.3 (range 0.67 -7.59) where as the mean%CV for high
control was 1.6 (range: 0.39- 7.19). The data collected
for the inter machine comparison between the three
reference analyzers at a single center at two different
out-patient clinics showed that the% CV between these
analyzers was 8% with a range of 2.4% to 9% (N= 25,
range of CD4 count: 114–965).
A total of 1790 participants were enrolled in the study
(958 Male and 832 Female). The median age of the partici-
pants was 36 years (range: 19 to 55 years). The data
showed excellent correlation between the CD4 counts
obtained by PIMA CD4 analyzer and the respective refer-
ence methods (N=1790, r = 0.921, p < 0.001, Figure 1A) at
all centers. The Bland Altman plot analysis for the agree-
ment between the values obtained with PIMA CD4
analyzer and the respective reference methods showed low
relative bias of 0.2% (Mean ± SD: -42 to 42) (Figure 1B).
















































Figure 1 Comparison of the CD4 counts obtained by PIMA analyzer and reference methods using venous blood from 1790 samples.
Figure 1A: Linear regression analysis: The CD4 counts obtained by PIMA CD4 analyzer at 21 centers are plotted on Y axis and the counts obtained
by the respective reference methods are plotted on X axis. Figure 1B: The agreement analysis using the Bland Altman plots. The percent relative
bias for PIMA analyzer and the respective reference method is plotted on the Y axis and the average of the CD4 count by both the methods is
plotted on X axis. The black line represents the mean% relative bias where as the blue lines represent the range of Mean ± SD.
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obtained using PIMA CD4 analyzer FACSCount
(r = 0.983, P < 0.01), FACSCalibur (r = 0.988, P < 0.01) and
Cyflow SL3 (r = 0.977, P < 0.01). The CD4 counts obtained
using PIMA analyzer were compared with those obtained
using either of the three reference methods at different
clinically relevant CD4 levels such as <250, 251–350,
351–500 and >500 cells/mm3 (Table 1). The differences
in the median CD4 counts obtained by the reference
method and the PIMA analyzer were not significant
(P > 0.05) for all CD4 ranges. The relative bias was also
ranged between −7 to 5.1%.
WHO recommends to initiate ART at CD4 count < 350
cells/mm3(1). Hence, the sensitivity and specificity of the
PIMA CD4 analyzer to identify patients with CD4 count
<350 cells/mm3 was found to be 91% indicating that the
chances of 9% wrong counts. When the data within the
CD4 range of 251–500 cells/mm3 was assessed it was
observed that 50% of the mismatched values were within
the 320 to 380 cells/mm3. The data was analyzed for in-
dividual reference analyzer (Table 2) which also showed
the sensitivity and specificity of the PIMA analyzer ran-
ged between 91 to 96% and the mean relative bias be-
tween −5 to 8%.Table 1 Comparison of CD4 counts obtained by PIMA analyze
CD4 Range (Cells/mm3) N Median CD4 C
Reference Method
All 1790 356 (2–1726)
<250 508 165 (2–250)
<350 877 228 (2–350)
251-350 369 298 (251–350)
351-500 423 417 (351–500)
>500 490 648 (502–1726)
*: The differences between the median CD4 counts obtained by the one of the refe
ranges (P > 0.05).In 175 patients, the finger prick sample was obtained
in addition to venous blood. The CD4 counts obtained
from the finger prick samples using PIMA CD4 analyzer
correlated well with the CD4 counts obtained by refer-
ence method, FACSCalibur using the venous blood
(r = 0.856, P < 0.01, Figure 2A) with a relative bias of
−9.1%(range: -46% to 27%, Figure 2B). The CD4 counts
obtained using PIMA analyzer on both, finger prick and
venous blood were also comparable with r = 0.854 and
slightly better relative bias on 2.8% (range: -37% to 43%)
(Figure 2C and D).
The users of the equipment at various centers
expressed that the analyzer was compact and hence
could fit in the small space available at the centers. The
equipment is battery operated, showed a battery backup
of 3–4 hours eliminating the requirement of continuous
electricity. The rate of invalid cartridges was 1 to 2 per-
cent at these centers and thus repeat testing needed to
be done in such cases.
Discussion
The present field based study showed that the PIMA
analyzer gave comparable results with the reference
methodologies for different CD4 ranges; one of ther and the reference methods within different CD4 ranges
ount (Range)* Cells/mm3 Mean relative bias (±2SD)
PIMA Analyzer
354 (6–1615) −1% (−43, 42)
168 (6–348) −7% (−65, 51)
225(6–542) 5% (−45,55)
299 (153–542) −2% (−40, 36)
415 (213–676) 0% (−30, 30)
637 (179–1615) 5.1% (−23, 33)
rence methods and the PIMA analyzer was statistically insignificant for all CD4
Table 2 Sensitivity of PIMA analyzer to identify patients




N Sensitivity Specificity Mean Relative
bias (±2SD)
FACSCalibur 121 96% 91% 4(−48, 56)
FACSCount 206 92% 91% −5( −49, 59)
Partec 550 91% 96% 8(−8.4, -7.6)
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technology. The study could analyze more than 300
samples (range 369 to 508) samples at each CD4 range;
<250, 251–350, 351–500 and >500 cells/mm3 and the
analysis showed very low relative bias within the PIMA
and reference methodologies. Before distribution of the
machines to various centers the inter machine compari-
son showed less than 10 percent%CV for both high and
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A
r=0.856
Figure 2 Comparison of the CD4 counts obtained from finger prick sa
regression analysis: The correlation between the CD4 counts obtained from
venous blood using FACSCalibur (2A) and PIMA (2C) (X axis) is assessed. Fig
The percent relative bias for CD4 counts from finger prick sample and the
(Figure 2D) is plotted on the Y axis and the average of the CD4 count by b
mean% relative bias of where as the blue lines represent the range of Meaor fresh blood samples indicating good precision. The
onsite inter-instrument variation was also within the
10% limit indicating the efficient use of PIMA analyzer
as POC machine. The sensitivity and specificity of the
PIMA analyzer to identify the patients with CD4 count
less than 350, was found to be 91%. This indicated that
the use of PIMA would put additional burden on the
treatment providers as the treatment would be given to
the patients who still have CD4 counts above 350. How-
ever the analysis showed that more than 50% mis-
matched results were between CD4 counts of 320 to
380; indicating that most of the patients would need
ART in short time. The previously reported study has
showed higher sensitivity but lower specificity to identify
patients with CD4 counts lower than 350 cells (8). Previ-
ous studies have also shown less precision for the finger
prick samples and also indicated that the finger prick
sample collection required adequate training for correct






















































mple and from paired venous blood. Figure 2A and C: Linear
finger prick sample using PIMA CD4 analyzer (Y axis) and from
ure 2B and D: The agreement analysis using the Bland Altman plots.
paired venous blood using FACSCalibur (Figure 2B) and PIMA
oth the samples is plotted on X axis. The black line represents the
n ± SD.
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analyzer with slightly less efficiency and also confirmed
the requirement of the operator training for proper col-
lection of finger prick sample to avoid multiple pricks. It
was observed that in case of insufficient and improper
finger-prick sample collection, the reliability of the CD4
counts by PIMA analyzer was questionable. Also our
study participants preferred to give venous blood sam-
ple. The primary reasons were requirement of blood col-
lection for other investigations using venous blood and a
fear of being subjected to multiple pricks if sufficient
volume of blood is not obtained in a single prick. Hence
the finger prick blood sample could be the method of
choice when only CD4 testing has to be carried out. The
PIMA CD4 analyzer is battery operated and the reagents
are stable at room temperature making it suitable for
use in the areas where the reliable electric supply is not
available and the ambient temperatures are often high.
The cartridges have shelf life of six months making it
suitable for remote areas where the shipment, delivery
and storage, would be difficult. The testing does not re-
quire any additional equipment. The analyzer can be
used after a minimum training and can be run by the
clinical staff such as nurses where multi-tasking may be
necessary due to shortage of trained staff or lack of suffi-
cient workload [12].
The stabilized blood samples could be tested reliably by
PIMA analyzer indicating amenability of the system for
participation in the External Quality Assurance Scheme.
Unlike other CD4 enumerating equipments, in PIMA
analyzer, the complete process of staining takes place in
the equipment itself. Hence the sample throughput
would be relatively low and the analyzer would be useful
at the centres with 10–20 patients load/day. However, it
is not expected that peripheral centres will have higher
patient load and more than one machine could be in-
stalled in the centres if required.
The countrywide national ART roll out programme in
India comprises of 300 ART centers and 550 linked cen-
ters with 3,64,000 adult populations on ART by January
2011 [13].The availability of CD4 counts in selected cen-
ters required either long distance travel for the patient
or transport of the sample to the laboratory. This
resulted in missed visits of the patients and problems in
patient management. The loss to follow up of HIV
infected patients after the diagnosis has been reported to
be in the range of 16 to 25% in India [14, personal com-
munication]. Although multiple factors are responsible
for loss to follow up, availability of CD4 testing at point
of care will help in reducing the number of clinic visits,
thus helping in reducing loss to follow up. A recent re-
port from Africa showed that POC CD4 testing could
successfully reduce the pretreatment loss to follow-up
[15]. Also the implementation of 350 CD4 count as acut off for ART initiation instead of earlier cutoff of 250
would increase the burden on CD4 testing facility.
Hence the decentralization of CD4 testing by providing
CD4 count at primary health centers in combination
with HIV diagnosis could enable proper monitoring of
disease progression and ART initiation at the primary
health centers only and would maximize the public
health benefit of POC technology.
The PIMA analyzer does not provide percentage of
CD4+ cells; hence, it would not be useful for monitoring
the paediatric population younger than 5 years. As the
movement of the paediatric patients/samples is difficult in
the periphery, unavailability of CD4 percentage at the per-
ipheral centre could be one of the limitations of this POC
machine. In such cases the dual platform technology can
be used by using absolute lymphocyte counts from
hematology analyzer or from peripheral blood smear and
the absolute CD4 counts from PIMA analyzer to calculate
CD4 percentages. However the disadvantages would be of
influence of the variation due to another system.
The cost of the PIMA analyzer is lesser than the avail-
able single platform CD4 machines and the cost of the
cartridge is around 10 US$ which is slightly higher
which might pose problem if not procured in bulk
amount where the cost benefit could be obtained.
In conclusion, the study showed that the POC PIMA
CD4 analyzer would be suitable for use in remote areas
with minimum or no infrastructure. The availability of the
CD4 counts on the same day of sample collection would
reduce the number of repeat visits and improve patient
management. Hence the integration of POC CD4 testing
into the national AIDS control program would facilitate
the better patient management in HIV infection.
Competing interests
The authors have declared that no competing interests exist.
Authors’ contributions
MT: Planning, execution, analysis of the data and manuscript writing. BM, NS,
SB: Execution of the study, data collection and training. SS: statistical analysis.
SK, BR, MS, NS, PT: Execution and manuscript writing. RP: Planning and
manuscript writing. All authors read and approved the final manuscript.
Acknowledgements
The authors would like to thank the clinical and laboratory staff of the 21
ART centers from India for conducting the CD4 count estimations by PIMA
analyzer and the reference methods and also to the study volunteers for
their participation. The study was funded by UNITAID.
Author details
1Department of Immunology, National AIDS Research Institute, G-73, MIDC,
Bhosari, Pune 411 026, India. 2National AIDS Control Organization, New Delhi,
India. 3Clinton Health Access Initiative, New Delhi, India.
Received: 9 July 2012 Accepted: 17 September 2012
Published: 21 September 2012
References
1. World Health Organization: Antiretroviral therapy for HIV infection in adults
and adolescents: Recommendations for a public health approach.
2010. http://whqlibdoc.who.int/publications/2010/9789241599764_eng.pdf.
Thakar et al. AIDS Research and Therapy 2012, 9:26 Page 7 of 7
http://www.aidsrestherapy.com/content/9/1/262. Phillips AN, Pillay D, Miners AH, Bennett DE, Gilks CF, Lundgren JD:
Outcomes from monitoring of patients on antiretroviral therapy in
resource limited settings with viral load, CD4 cell count, or clinical
observation alone: a computer simulation model. Lancet 2008,
371:1443–1451.
3. Lawn SD, Little F, Bekker LG, Kaplan R, Campbel E, Orrell C, Wood R:
Changing mortality risk associated with CD4 cell response to
antiretroviral therapy in South Africa. AIDS 2009,
23:335–342.
4. Sterne JA, May M, Costagliola D, de Wolf F, Phillips AN, Harris R, Funk MJ,
Geskus RB, Gill J, Dabis F, Miró JM, Justice AC, Ledergerber B, Fätkenheuer G,
Hogg RS, Monforte AD, Saag M, Smith C, Staszewski S, Egger M, Cole SR:
When To Start Consortium: Timing of initiation of antiretroviral therapy
in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV
cohort studies. Lancet 2009, 373:1352–1363.
5. UNAIDS: Report on the global AIDS epidemic. 2010.
http://www.unaids.org/globalreport/Global_report.htm.
6. Sukapirom K, Onlamoon N, Thepthai C, Polsrila K, Tassaneetrithep B,
Pattanapanyasat K: Performance Evaluation of the Alere PIMA CD4 Test
for Monitoring HIV-Infected Individuals in Resource-Constrained Settings.
J Acquir Immune Defic Syndr 2011, 58(2):141–147.
7. Mtapuri-Zinyowera S, Chideme M, Mangwanya D, Mugurungi O, Gudukeya
S, Hatzold K, Mangwiro A, Bhattacharya G, Lehe J, Peter T: Evaluation of the
PIMA point-of-care CD4 analyzer in VCT clinics in Zimbabwe. J Acquir
Immune Defic Syndr 2010, 55(1):1–7.
8. Papa Alassane D, Géraldine D, Abdoul Aziz C, Birahim Pierre N, Djibril W,
Makhtar CamaraSouleymane M, Luc K, Tandakha Ndiaye D: Multisite
Evaluation of a Point-of-Care Instrument for CD4+ T-Cell Enumeration
Using Venous and Finger-Prick Blood: The PIMA CD4. J Acquir Immune
Defic Syndr 2011, 58:103–111.
9. Pattanapanyasat K, Phuang-Ngern Y, Sukapirom K, Lerdwana S, Thepthai C,
Tassaneetrithep B: Comparison of 5 flow cytometric immunophenotyping
systems for absolute CD4+ T-lymphocyte counts in HIV-1-infected
patients living in resource-limited settings. J Acquir Immune Defic Syndr
2008, 49(4):339–347.
10. Zijenah LS, Kadzirange G, Madzime S, Borok M, Mudiwa C, Tobaiwa O,
Mucheche M, Rusakaniko S, Katzenstein DA: Affordable flow cytometry for
enumeration of absolute CD4+ T-lymphocytes to identify subtype C
HIV-1 infected adults requiring antiretroviral therapy (ART) and
monitoring response to ART in a resource-limited setting. J Transl Med.
2006, 4:33.
11. Bland JM, Altman DG: Statistical methods for assessing agreement
between two methods of clinical measurement. Lancet 1986,
1:307–310.
12. Jani IV, Sitoe NE, Chongo PL, Alfai ER, Quevedo JI, Tobaiwa O, Lehe JD,
Peter TF: Accurate CD4 T-cell enumeration and antiretroviral drug
toxicity monitoring in primary healthcare clinics using point-of-care
testing. AIDS 2011, 25:807–812.
13. Annual Report, 2010-11. National AIDS Control Organization: Department of
AIDS Control, Ministry of Health & Family Welfare Government of India.
http://www.nacoonline.org/upload/REPORTS/NACO%20Annual%20Report%
202010-11.pdf.
14. Bachani D, Garg R, Rewari B, Hegg L, Rajasekaran S, Deshpande A,
Emmanuel K, Polin C, Rao S: Two-year treatment outcomes of patients
enrolled in India’s national first-line antiretroviral therapy programme.
Natl Med J India 2010, 23(1):7–12.
15. Jani IV, Sitoe NE, Alfai ER, Chongo PL, Quevedo JI, Rocha BM, Lehe JD, Peter
TF: Effect of point-of-care CD4 cell count tests on retention of patients
and rates of antiretroviral therapy initiation in primary health clinics: an
observational cohort study. Lancet. doi:10.1016/S0140-6736(11)61052-0.
Published online September 26, 2011.
doi:10.1186/1742-6405-9-26
Cite this article as: Thakar et al.: Utility of the point of care CD4 analyzer,
PIMA, to enumerate CD4 counts in the field settings in India. AIDS
Research and Therapy 2012 9:26.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
